|
drgunasakaran1 ★★ 2013-10-24 17:43 (4629 d 23:14 ago) @ Clarc Posting: # 11751 Views: 6,158 |
|
|
Dear Clarc, ❝ Can I define in the protocol a widening to 0.75-1.33, or I have to perform a reference scaled bioequivalence? For EU submission, it is suggested to go for Expandable BE limits as per EMA's Guideline on the Investigation of Bioequivalence — Dr Gunasakaran Sambandan MD Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn |
|
Helmut ★★★ ![]() Vienna, Austria, 2013-10-25 16:56 (4629 d 00:01 ago) @ Clarc Posting: # 11768 Views: 6,005 |
|
|
Hi Clarc, ❝ Our statistical software doesn't permit scaling, only widening to 0.75-1.33. The design is a fully replicated TRTR/RTRT design. May I guess: Kinetica? If yes, AFAIK you cannot evaluate replicate designs at all. ❝ Can I define in the protocol a widening to 0.75-1.33, You could, but it will not be accepted… ❝ or I have to perform a reference scaled bioequivalence? Yes – see Dr. Gunasakaran’s post above. Don’t forget two obstacles:
— Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |

![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
![[image]](https://static.bebac.at/img/CC by.png)
